SCHEMBL252367

SCHEMBL252367

CC(C)N(C(C)C)P(O)OCCC#N

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.30
NLRP3 Q96P20 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7858703 1.00 TSHR (0.30) TSHRNLRP3
SCHEMBL7262903 1.00 TSHR (0.30) TSHRNLRP3
Hydrochloric Acid SCHEMBL25380883 0.98
SCHEMBL5067027 0.92
SCHEMBL5063697 0.92
Glycerin SCHEMBL7951846 0.90
SCHEMBL5065012 0.90
SCHEMBL26653603 0.90
SCHEMBL23384350 0.90 TSHR (0.31) TSHR
SCHEMBL9235878 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1800 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103480-A1 NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME SANOFI SA (FR) 2026-04-16 US claimed
US-20250092082-A1 PHOTON GENERATING SUBSTRATES FOR OLIGONUCLEOTIDE SYNTHESIS MICROSOFT TECHNOLOGY LICENSING, LLC 2025-03-20 US claimed
CN-112105625-B Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same 赛诺菲 2024-12-31 CN claimed
CN-119173522-A Methods and compounds ATD生物有限公司 2024-12-20 CN claimed
US-20240376137-A1 NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME SANOFI SA (FR) 2024-11-14 US claimed
CN-118178675-A Supermolecule DNA-PEG-Ferrocene nano gel, preparation method and anti-tumor application 武汉科技大学 2024-06-14 CN claimed
EP-4367244-A1 OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF Ractigen Therapeutics (CN) 2024-05-15 EP claimed
CN-117916374-A Oligonucleotide-based delivery vehicles for oligonucleotide agents and methods of use thereof 中美瑞康核酸技术(南通)研究院有限公司 2024-04-19 CN claimed
EP-4341270-A1 CHEMICAL PHOSPHORYLATION REAGENTS, PREPARATION, AND THEIR USES Olix US, Inc. (US) 2024-03-27 EP claimed
CN-117580848-A Chemical phosphorylating reagent, preparation and use thereof 奥利克斯美国公司 2024-02-20 CN claimed
WO-2001052902-A1 ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2001-07-26 WO claimed
EP-1019534-A1 MULTIFUNCTIONAL LINKING REAGENTS FOR SYNTHESIS OF BRANCHED OLIGOMERS BIOGENEX LABORATORIES (US) 2000-07-19 EP claimed
WO-2000040590-A2 FUNCTIONALISED POLYNUCLEOTIDE COMPOUND, OPTIONALLY MARKED AND METHOD FOR DETECTING A TARGET NUCLEIC ACID BIO MERIEUX (FR) 2000-07-13 WO claimed
US-5916750-A NON-NUCLEOSIDIC PHOSPHORAMIDITES BASED ON 1,3,5-TRIS(2-HYDROXYETHYL)CYANURIC ACID USED TO CONSTRUCT MULTIPLY-LABELED, BRANCHED DNA OLIGOMER PROBES BIOGENEX LABORATORIES (US) 1999-06-29 US claimed
WO-1998030719-A1 MULTIFUNCTIONAL LINKING REAGENTS FOR SYNTHESIS OF BRANCHED OLIGOMERS BIOGENEX LABORATORIES (US) 1998-07-16 WO claimed
EP-0759927-B1 PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES US GOV HEALTH & HUMAN SERV (US) 1998-06-24 EP claimed
US-5677439-A PREVENTION GENE EXPRESSION SANOFI (FR) 1997-10-14 US claimed
US-5648480-A Process for making oligonucleotides having modified internucleoside linkages NORTHWESTERN UNIVERSITY (US) 1997-07-15 US claimed
US-5218102-A Easily synthesized, hybridize well with target sequences IMPROBIO (BE) 1993-06-08 US claimed
EP-0334694-A1 Nucleic acid probes with non-radioactive labels, and preparation processes LA REGION WALLONNE (BE) 1989-09-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103480-A1 NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME NSUN2, NSUN3, SNRPA TSHR 1010/4885NLRP3 4097/4885
US-20240376137-A1 NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME RNMT, NSUN2, ADAR TSHR 3889/4885NLRP3 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.